Hyderabad (Telangana) [India], January 23: Sigachi Industries Ltd. (NSE: SIGACHI; BSE: 543389), a leading Indian pharmaceutical company, today announced a significant milestone in its research and development pipeline with the successful advancement of a new Cystic Fibrosis (CF) Active Pharm
Researchers found that airway mucus is less sticky and lung inflammation is greatly reduced if triple combination treatment is used for long-term benefits in people with cystic fibrosis (CF). According to their research, this type of drug relieves the symptoms of CF in many people.
Mucus in the airways is less sticky, and lung inflammation is greatly reduced: In individuals with cystic fibrosis (CF), triple combination treatment can produce these long-term benefits.